Laparoscopy firm SurgRx attracts former Novacept backer in fundraising
This article was originally published in Clinica
Executive Summary
New Enterprise Associates, the long-established venture capital firm that backed Novacept through to its acquisition by Cytyc for $325m last year, has led a $21m investment round in SurgRx. Menlo Park, California-based SurgRx has developed an FDA-approved laparoscopic instrument, EnSeal, that operates via a radiofrequency controller and "Smart Electrode" sensor to cut and seal blood vessels and tissue while minimising thermal damage to adjacent tissue.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.